0000899243-20-000614.txt : 20200106 0000899243-20-000614.hdr.sgml : 20200106 20200106180945 ACCESSION NUMBER: 0000899243-20-000614 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200106 DATE AS OF CHANGE: 20200106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shannon John Patrick Jr CENTRAL INDEX KEY: 0001553595 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 20511435 MAIL ADDRESS: STREET 1: DURATA THERAPEUTICS, INC. STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR CITY: MORRISTOWN STATE: NJ ZIP: 07960 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-31 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001553595 Shannon John Patrick Jr C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 0 1 0 0 See Remarks Common Stock 2019-12-31 5 A 0 E 438 5.99 A 10559 D These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from July 1, 2019 through December 31, 2019. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2019. Executive Vice President and Chief Operating Officer /s/ Beth Hecht, as Attorney-in-Fact 2020-01-06